Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAXO trial
2024-520288-15-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine and fluorouracil in metastatic colon cancer (mCRC) and colorectal cancer (CRC), sponsored by Helsinki University Hospital. Primary endpoints: Clinical behaviour and resectability of metastatic colorectal cancer, Postoperative morbidity after resection and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
capecitabinefluorouracil
03
Conditions
metastatic colon cancer (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-520288-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520288-15-00.